Press Release

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients…

SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with…

BARCELONA, 10 April 2024 – SpliceBio, a genetic medicines company harnessing Protein Splicing to develop…

Dr. Girach is a world-renowned specialist in the field of ophthalmology and gene therapy Appointment…

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus…

Dr. Favre brings extensive experience in gene therapy, immunology and drug development Appointment comes at…

BARCELONA, January 26, 2023 – SpliceBio, a genetic medicines company on a mission to expand…

Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde…

BARCELONA, January 21, 2021 – Splice Bio, a gene therapy company based on technology developed…

BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in…